NCT05661084

Brief Summary

This project aims to examine the efficacy of remote, caregiver-led tES/brain stimulation intervention targeted to improve memory, mobility, and executive functioning among older adults with mild cognitive impairment or mild dementia.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
144

participants targeted

Target at P75+ for not_applicable

Timeline
16mo left

Started Jan 2023

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress71%
Jan 2023Aug 2027

First Submitted

Initial submission to the registry

August 25, 2022

Completed
4 months until next milestone

First Posted

Study publicly available on registry

December 22, 2022

Completed
1 month until next milestone

Study Start

First participant enrolled

January 24, 2023

Completed
3.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2027

Last Updated

January 12, 2026

Status Verified

January 1, 2026

Enrollment Period

3.9 years

First QC Date

August 25, 2022

Last Update Submit

January 8, 2026

Conditions

Keywords

Alzheimer's DiseaseDementiaMemoryBrain Stimulationtranscranial alternating current stimulation (tACS)transcranial direct current stimulation (tDCS)Executive functioninstrumental activities of daily living (IADL)

Outcome Measures

Primary Outcomes (2)

  • Change in Rey Auditory Verbal Learning Test (RAVLT) Total Recall

    This test is designed to evaluate verbal memory in those 16 years of age and older. It can be used to evaluate the nature and severity of memory dysfunction and to track changes in memory function over time. Total recall is measured by the total number of words out of 15 the participant is able to recall. Scores range from 0 to 15.

    baseline, immediate post-intervention, 3 month follow up , 6 month follow up

  • Change in Dual Task Cost to Gait

    This measure is captured by Mobility Labâ„¢ (APDM Inc) software while the participant is walking with sensors at a) normal speed (speed for single task) and b) walking while counting backwards by 3's or 1's (speed dual task). The formula for cost of the dual task to gait is: (speedsingletask-speeddualtask)/speedsingletask)\*100). Range for dual task cost is as follows: High Risk for falls \> 0.2, Moderate Risk for falls \<= 0.2, Low Risk \< 0.1.

    baseline, immediate post-intervention, 3 month follow up, 6 month follow up

Secondary Outcomes (10)

  • Change in Functional Activity Questionnaire

    baseline, immediate post-intervention, 3 month follow up, 6 month follow up

  • Change in Montreal Cognitive Assessment (MoCA) total score, memory and executive subscores

    baseline, immediate post-intervention, 3 month follow up, 6 month follow up

  • Average E-field normal component (En) for left angular gyrus and prefrontal cortex

    immediate post-intervention

  • Change in Adjusted Trail Making Test performance

    baseline, immediate post-intervention, 3 month follow up, 6 month follow up

  • Change in Stroop test response latency

    baseline, immediate post-intervention, 3 month follow up, 6 month follow up

  • +5 more secondary outcomes

Study Arms (4)

tACS(AG) + tDCS(PFC) combo active

EXPERIMENTAL

Participants (Ps) will undergo 20min of daily home-based tACS active + tDCS active intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).

Device: Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (active)

tACS(AG) active + tDCS(PFC) sham

ACTIVE COMPARATOR

Participants (Ps) will undergo 20min of daily home-based tACS active + tDCS sham intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).

Device: Transcranial alternating current stimulation (tACS) (active); Transcranial direct current stimulation (tDCS) (sham)

tACS(AG) sham + tDCS(PFC) active

ACTIVE COMPARATOR

Participants (Ps) will undergo 20min of daily home-based tACS sham + tDCS active intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).

Device: Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (active)

tACS(AG) sham + tDCS(PFC) sham

SHAM COMPARATOR

Participants (Ps) will undergo 20min of daily home-based tACS sham + tDCS sham intervention over the left angular gyrus and prefrontal cortex for 4 weeks by their trained caregiver/administrators (As).

Device: Transcranial alternating current stimulation (tACS) (sham); Transcranial direct current stimulation (tDCS) (sham)

Interventions

Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex.

Also known as: Transcranial electrical stimulation (tES)
tACS(AG) + tDCS(PFC) combo active

A sham transcranial electrical stimulation (tES) will be administered to the participant in their home by their caregiver administrator to the left angular gyrus and prefrontal cortex. It will physically mimic active stimulation.

Also known as: Transcranial electrical stimulation (sham condition)
tACS(AG) sham + tDCS(PFC) sham

Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Active tACS to the left angular gyrus and sham tDCS to the prefrontal cortex.

Also known as: tACS active; tDCS sham
tACS(AG) active + tDCS(PFC) sham

Transcranial electrical stimulation (tES), via alternating and direct current, will be administered to the participant in their home by their caregiver administrator. Sham tACS to the left angular gyrus and active tDCS to the prefrontal cortex.

Also known as: tACS sham; tDCS active
tACS(AG) sham + tDCS(PFC) active

Eligibility Criteria

Age55 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Participants (Ps)
  • willing and capable to give informed consent for the participation in the study after it has been thoroughly explained
  • able and willing to comply with all study requirements
  • an informed consent form was signed
  • able to read, write, and communicate in English
  • Caregiver/Administrators (As)
  • at least 18 years of age
  • able to read, write, and communicate in English
  • self-reported computer proficiency and willingness to learn how to use tES as defined by "yes" answers to the questions "Do you feel comfortable using a computer?" and "Are you willing to be the primary caregiver for a participant and learn how to administer tES?"
  • stated availability during weekdays throughout the study period to administer tES to the Ps

You may not qualify if:

  • Participants (Ps)
  • major psychiatric co-morbidity including major depressive disorder, schizophrenia or psychosis
  • blindness or other disabilities that prevent task performance
  • contraindications to tES, as recorded on a standardized screening questionnaire, which include a reported seizure within the past two years, use of neuroactive drugs, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, etc.)
  • the presence of any active dermatological condition, such as eczema, on the scalp a score of 18 or less on the Montreal Cognitive Assessment (MoCA) during the in-person screen
  • an inability to understand study procedures following review of the Informed Consent form
  • Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the "Assessment of Protocol Understanding" form. Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator
  • Caregiver/Administrators (As)
  • mild cognitive impairment defined by a MoCA score ≤26 during the in-person screen
  • insufficient understanding of study procedures following review of the Informed Consent form
  • Understanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the "Assessment of Protocol Understanding" form. Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator.
  • poor eyesight, severe arthritis in the hands, pain, deformity or other condition that interferes with successful administration of tES

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hinda and Arthur Marcus Institute for Aging Research

Boston, Massachusetts, 02131, United States

RECRUITING

MeSH Terms

Conditions

DementiaMemory DisordersAlzheimer DiseaseMobility Limitation

Interventions

Transcranial Direct Current Stimulation

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System DiseasesNeurocognitive DisordersMental DisordersNeurobehavioral ManifestationsNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsTauopathiesNeurodegenerative Diseases

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsConvulsive TherapyPsychiatric Somatic TherapiesBehavioral Disciplines and ActivitiesElectroshockPsychological Techniques

Study Officials

  • Alvaro Pascual-Leone, MD; PhD

    Hebrew SeniorLife

    PRINCIPAL INVESTIGATOR
  • Brad Manor, PhD

    Hebrew SeniorLife

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Double-blind, sham controlled
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Randomized, sham-controlled, double-blinded, parallel-arm trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 25, 2022

First Posted

December 22, 2022

Study Start

January 24, 2023

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

August 31, 2027

Last Updated

January 12, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will share

The prospective plan is to have data available in a data dementia-related data repository.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
This is a multi-year study and the data will be available at the finish, when the data is unblinded.
Access Criteria
Depending on the repositories in which the data is held. However, use of the data will be restricted by permission and appropriate human subjects review of the prospective project.

Locations